Latest Grifols S.A. Stories
BARCELONA, Spain, April 1, 2015 /PRNewswire/ -- Grifols, S.A.
- Three-year commitment of up to 20 million units per year of blood clotting medicines to treat hemophilia patients in developing countries BARCELONA, Spain, April 17, 2014 /PRNewswire/
BARCELONA, Spain, April 4, 2014 /PRNewswire/ -- Grifols, S.A.
Reportbuyer.com just published a new market research report:
BARCELONA, Spain, June 3, 2011 /PRNewswire/ -- Grifols, S.A. (NASDAQ: GRFS) ("Grifols") a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that on June 1, 2011, Grifols completed its acquisition of Talecris Biotherapeutics Holdings Corp.